Effects of Melatonin on IL-6 Serum Level Changes and Fatigue Caused by Adjuvant Chemoradiotherapy in Breast Cancer Women: A Randomized Controlled Trial

Pashaki, Abdolazim Sedighi; Afshar, Saeid; Mohamadian, Kamal; Gholami, Mohamad Hadi; Moradi, Abbas; Amlashi, Zahra Keshtpour

doi:10.30699/ijbd.13.4.23

Cited by 3 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…16 Subsequently, we showed the efficacy of melatonin in the management of fatigue in breast cancer patients. 24 In the current study, the BFI score was similar before the intervention in both groups. After the intervention (18 mg/day of oral melatonin), not only both the mean fatigue score and severity of fatigue were significantly lower in melatonin group ( P ≤ .05), but a greater decrease in fatigue score in the intervention group is evident over time ( P ≤ .001).…”

Section: Discussionsupporting

confidence: 54%

A Randomized, Controlled, Parallel-Group, Trial on the Long-term Effects of Melatonin on Fatigue Associated With Breast Cancer and Its Adjuvant Treatments

et al. 2023

Self Cite

View full text Add to dashboard Cite

Objective: Cancer related fatigue is a distressing condition and correlated with decrease in quality of life of patients with malignant conditions. In continuation of our previous research, we assessed long term anti-fatigue effects of melatonin in patients with the breast cancer. Material and methods: In this clinical trial, 92 breast cancer patients were randomly assigned to receive either melatonin (18 mg/day) or placebo from 1 week before the adjuvant treatments until 2 years after their completion. The levels of fatigue were assessed before and after intervention using Brief Fatigue Inventory (BFI) and were compared at a significance level of P ≤ .05. Results: The BFI scores were similar between the 2 groups at the baseline (placebo group: 5.56 ± 1.59 and melatonin group: 5.72 ± 1.68, P = .67). After the intervention, not only the mean fatigue score was significantly lower in melatonin group (2.93 ± 1.04 vs 1.99 ± 1.02, P < .001, P ≤ .05), but also a greater reduction in fatigue score in intervention group was evident over time ( P ≤ .001). Conclusion: Long-term usage of melatonin even after completion of adjuvant therapies in women with breast cancer decreased the levels of fatigue associated with the malignant condition and its treatments. The trial registry name and URL, and registration number: Iranian Registry of Clinical Trials, https://en.irct.ir/trial/62267 , IRCT20180426039421N3

show abstract

Section: Discussionsupporting

confidence: 54%

A Randomized, Controlled, Parallel-Group, Trial on the Long-term Effects of Melatonin on Fatigue Associated With Breast Cancer and Its Adjuvant Treatments

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…Breast cancer is the major cause of cancer-related deaths in women worldwide. 1 , 2 Despite many years of research, cancer is still a main cause of death. Breast cancer is common worldwide, but in cases of early diagnosis and treatment, the probability of recovery is high and patients often have a long life.…”

Section: Introductionmentioning

confidence: 99%

The Effect of Melatonin on Increasing the Health Related Quality of Life in Non-Metastatic Breast Cancer Patients: Three-Year Follow up a Clinical Trial

Keshtpour Amlashi,

Sheida,

Anbiaee

et al. 2024

Integr Cancer Ther

Self Cite

View full text Add to dashboard Cite

Introduction: Although breast cancer is common worldwide, if diagnosed early and treated on time, the probability of recovery is high and patients often experience a long life. Reducing the quality of life is a common side effect in patients. Melatonin may have an important role in fatigue, sleep disorders and, as a result, the health-related quality of life (HRQoL) in people. About 184 patients with breast cancer were enrolled in 2 groups: intervention with daily melatonin intake of 18 mg for 3 years (93 patients) and the control group with placebo intake (91 patients). Health-related quality of life and the effect of melatonin on increasing that were evaluated with the EORTC QLQ-C30 questionnaire, third edition at the beginning, 2 months later and 3 years after the beginning of the study. Results: The general score of the HRQoL was significantly different both in the passage of time and in the comparative study of the 2 groups, and it was better in the melatonin group ( P < .05). Conclusion: Long-term use of 18 mg of melatonin for 3 years in patients with non-metastatic breast cancer can lead to an increase in the patients’ quality of life.

show abstract

“…After screening the titles and abstracts, 1111 articles were excluded, and 50 papers were retrieved for full text review. Out of 50 retrieved papers, 1 article was excluded due to wrong languages,22 6 articles were excluded without complete data, 14 articles were excluded without full text, 9 articles were excluded without target outcome and 1 article was excluded due to a non-RCT study 23. Therefore, a total of 19 articles were included in the final meta-analysis 24–42.…”

Section: Resultsmentioning

confidence: 99%

Effect of melatonin on quality of life and symptoms in patients with cancer: a systematic review and meta-analysis of randomised controlled trials

Fan

Yang

et al. 2022

BMJ Open

View full text Add to dashboard Cite

ObjectiveThis study systematically reviewed the effect of melatonin (MLT) on quality of life (QoL) and symptoms among patients with cancer.DesignSystematic review and meta-analysis.Data sourcesCochrane Library, PubMed, Embase, Web of Science, Medline, CINAHL, Scopus, ClinicalTrials.gov, China Biology Medicine (CBM), ProQuest and Open Grey were searched from inception to November 2021.Eligibility criteriaWe included randomised controlled trials (RCTs) assessing the effects of MLT on QoL, sleep quality, fatigue, depression, pain, stomatitis rate and stomatitis severity in adult patients with cancer, without language restrictions. Studies that reported the effects of MLT along with other interventions and had incomplete or absent outcome data were excluded.Data extraction and synthesisTwo independent reviewers extracted data, and another two reviewers assessed the risk of bias. The risk of bias for each eligible study was assessed using the Cochrane assessment tool. The mean difference or standard mean difference (SMD) with 95% CIs was used in the computation of continuous variables to synthesise data. The relative risk was used for dichotomous outcomes. Heterogeneity was assessed and quantified (I2 statistic).ResultsA total of 19 qualified studies that included 2101 patients with cancer (MLT: 1078, control: 1023) were included in the meta-analysis. The results indicated that MLT had no significant effect on QoL (SMD=−0.01, 95% CI (−0.14 to 0.11), p=0.83), sleep quality (SMD=−0.18, 95% CI (−0.62 to 0.26), p=0.42), fatigue (SMD=−0.34, 95% CI (−0.73 to 0.06), p=0.10), pain (SMD=−0.34, 95% CI (−0.7 to 0.02), p=0.06) or stomatitis severity (RR=0.78, 95% CI (0.47 to 1.30), p=0.35). MLT reduced stomatitis rate among patients with cancer (RR=0.47, 95% CI (0.26 to 0.88), p=0.02), except those with head and neck cancer (RR=1.09, 95% CI (0.92 to 1.29), p=0.35). MLT eased depression in patients who received administration for more than 14 days (SMD=−0.14, 95% CI (−0.27 to –0.01), p=0.03) and those who underwent surgery (SMD=−0.17, 95% CI (−0.32 to –0.03), p=0.02).ConclusionThe findings showed that MLT did not improve the QoL, sleep quality, fatigue, pain or stomatitis severity among patients with cancer. It had a limited effect on decreasing the stomatitis rate and easing depression. Different treatments, durations and cancer types were the main sources of heterogeneity. Further large-scale RCTs are urgently needed. In addition, the effects of different combinations of MLT dosage and duration, administration types and joint measures are worthy of further study.PROSPERO registration numberCRD42021292855.

show abstract

Effects of Melatonin on IL-6 Serum Level Changes and Fatigue Caused by Adjuvant Chemoradiotherapy in Breast Cancer Women: A Randomized Controlled Trial

Cited by 3 publications

References 4 publications

A Randomized, Controlled, Parallel-Group, Trial on the Long-term Effects of Melatonin on Fatigue Associated With Breast Cancer and Its Adjuvant Treatments

A Randomized, Controlled, Parallel-Group, Trial on the Long-term Effects of Melatonin on Fatigue Associated With Breast Cancer and Its Adjuvant Treatments

The Effect of Melatonin on Increasing the Health Related Quality of Life in Non-Metastatic Breast Cancer Patients: Three-Year Follow up a Clinical Trial

Effect of melatonin on quality of life and symptoms in patients with cancer: a systematic review and meta-analysis of randomised controlled trials

Contact Info

Product

Resources

About